Ballerup, Denmark, 20 August 2015 – This agreement is one in a series of recent deals for LEO Pharma and illustrates the company’s ambition to provide easy access to better care solutions for people with skin diseases.
“The Internet is dramatically changing how consumers manage their health and this creates new opportunities for us to deliver innovative, value-added services and LEO Pharma wants to be at the forefront of that trend,” said Kim Kjoeller, Senior Vice President of Global Development at LEO Pharma. “I’m very pleased to announce our investment in SkinVision as this deal will provide access to unique digital learnings that will ultimately help us address the unmet needs of individual patients in an ever changing and increasingly digital healthcare environment.”
SkinVision is known for its early self-detection skin assessment app for smartphones. The current focus area of the app is melanoma – but is likely to expand into other skin disease areas.
“We are delighted to reach this agreement with LEO Pharma, because it will enable us to expand into new areas and it validates our approach,” said Dick Uyttewaal, CEO of SkinVision B.V. “LEO Pharma has a great reputation and range of products in the treatment of skin conditions, so there is clear synergy between the two companies. We want to be the leading provider of digital solutions for skin conditions and together with LEO Pharma we believe we can provide consumers with even more personalised, informative healthcare services.”
The overall agreement covers both an equity investment as well as a Letter of Intent outlining possible future collaboration projects.
LEO Pharma has invested in SkinVision along with majority shareholder Personal Health Solutions (PHS) Capital, a Dutch investment firm focusing on science based, technology enabled solutions that provide an enhanced quality of life and reduces the risk of chronic illness.
About SkinVision B.V.
SkinVision is a consumer centric digital health company for dermatology with a robust big data infrastructure to help people achieve healthy skin. The first priority of SkinVision is the early detection of skin cancer. The company was founded in 2012, is headquartered in Amsterdam in Netherlands and has 12 employees. For more information, visit www.skinvision.com
About the SkinVision App
The application works by users taking pictures of moles, which are then analysed using an algorithm to identify potential abnormal growth. The app evaluates the risk level with an online assessment based on a traffic light of red, orange or green. Characteristics of unnatural growth could indicate a developing melanoma (code red), or if further research is needed (code orange). In both cases, the patient is referred to a dermatologist. Users can archive their skin lesions to track for changes over time or can share the images with their doctor through the app when they feel uncomfortable. The application has received European CE certification, following its scientific testing by the university clinic of Ludwig Maximillian University (LMU) in Munich, Germany, in 2013.
Note: The application is not a diagnostic device and does not replace a visit to the doctor.
About LEO Pharma A/S
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, the company supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to delivering products and solutions to people suffering from skin diseases. LEO Pharma is headquartered in Denmark and employs around 4,800 people worldwide. For more information, visit www.leo-pharma.com
Subscribe to our YouTube channel: www.youtube.com/leopharmaglobal
Follow us on Twitter: www.twitter.com/leohealthyskin
Visit us at LinkedIn: www.linkedin.com/company/leo-pharma